About CSL Behring
Vision and Values
Research and Development
The CSL Behring Mission
CSL Behring is a global leader in the plasma protein biotherapeutics industry. We research, develop, manufacture and market biotherapies to treat rare, often life-threatening conditions. Our customers rely on our therapies to help them live better and, in many cases, longer lives.
CSL Behring’s commitment to changing the lives of people with serious and rare conditions shows in everything we do. Whether manufacturing and marketing safe and effective products or researching and developing innovative biotherapies, our first and foremost focus is always on fulfilling our customers' needs.
What are Biotherapies?
Biotherapies are very different from traditional pharmaceuticals. First, they do not derive from chemicals, but derive from human plasma or are produced as recombinant equivalents to human plasma. These biologic source materials are very expensive, and due to their biologic origins, biotherapies must undergo rigorous safety controls and inspections throughout every step of a year-long manufacturing process that extends from the collection of plasma to the final packaging of the finished product. The initial cost of the source materials and the painstaking process of ensuring their safety mean that the material cost of biotherapies is typically much higher than traditional pharmaceuticals, which are largely chemically-derived pills. In fact, the costs of production for plasma-derived medical therapies typically represent about 70% of the selling price compared to an average of 19% for chemical-based pharmaceuticals.
Second, while many traditional pharmaceuticals treat millions of patients worldwide, biotherapies generally treat much smaller patient populations. As a result, economies of scale in the biotherapeutics industry are much narrower than in the traditional pharmaceutical industry, and biotherapies are products that address patient populations with highly specialized, often very severe needs.
The Products of CSL Behring
At CSL Behring, we provide products that address a variety of conditions, many of them life-threatening. Among the targets of CSL Behring biotherapies are various coagulation (bleeding) disorders, including hemophilia and von Willebrand disease; primary immunodeficiencies; hereditary angioedema; and genetic emphysema. Our biotherapies are also used in critical care settings to treat shock, sepsis and severe burns; during cardiac surgery; and to facilitate wound healing. In addition, we provide biotherapies that help prevent hemolytic disease in the newborn resulting from Rh factor incompatibilities, and that help protect against cytomegalovirus disease in transplant patients.
Our products are produced in accordance with international safety and quality standards at facilities around the world, including in Australia; Bern, Switzerland; Marburg, Germany; Broadmeadows, Australia; and Kankakee, Illinois. The company also operates CSL Plasma, one of the world’s largest plasma collection networks throughout the United States and Germany. CSL Behring employs over 9,000 people in 19 countries.
At CSL Behring, we are passionate about safety and quality, and especially about the customers whose needs we serve. Our extensive research and development and range of support services demonstrate our ongoing commitment to saving and improving the lives of the people who rely on our products.